917 completed, 282 terminated, 266 recruiting, 189 unknown. 820 Phase 2, 610 Phase 1, 229 Not applicable, 122 Phase 3, 32 Early Phase 1.
Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-11-20 |
| Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 10 | 2027-04-26 | 2026-11-09 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma Neoadjuvant Pembrolizumab, Belzutifan, Lenvatinb - Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Vall d'Hebron Institute of Oncology | 150 | 2027-01-01 | 2026-11-12 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Metabolism And Diet for Improving Kidney Cancer Health (MACH3) Health Coaching, Time-Restricted Eating, Mediterranean Diet - Renal Cell Carcinoma | Not applicable | Not yet recruiting | University of Miami | 30 | 2026-12-21 | 2026-11-18 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2026-09-09 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus | Not yet recruiting | Liu Zhuo | 273 | 2026-11-30 | 2026-10-28 | |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
| AI-Based Anatomy Recognition in Minimally Invasive Kidney Surgery AI-based intra-operative anatomical perception system - Kidney (Renal Cell) Cancer, Ureteropelvic Junction Obstruction | Not yet recruiting | Chinese PLA General Hospital | 1700 | 2026-11-15 | 2026-11-17 | |
| Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma Pucotenlimab, Lenvatinib, Stereotactic Body Radiotherapy - Localized Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2026-11-10 | 2026-11-06 |
| Evaluation of Safety, Pharmacokinetics, Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM 68Ga-NYM096 injection - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Recruiting | Norroy Bioscience Co., LTD | 20 | 2026-11-08 | 2026-11-19 |
| Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno) Bio-specimen Collection, Blood Draw - Prostate Cancer, Renal Cell Carcinoma (RCC) | Recruiting | University of Oklahoma | 300 | 2026-11-02 | 2026-10-13 |
Showing 20 of 1968. Sign in to see all of them.
Kidney Neoplasms (480) · Melanoma (290) · Carcinoma, Non-Small-Cell Lung (285) · Neoplasm Metastasis (170) · Neoplasms (158) · Colorectal Neoplasms (147) · Breast Neoplasms (142) · Carcinoma, Hepatocellular (135) · Ovarian Neoplasms (120) · Squamous Cell Carcinoma of Head and Neck (116) · Stomach Neoplasms (115) · Urinary Bladder Neoplasms (115) · Pancreatic Neoplasms (109) · Prostatic Neoplasms (101)
Female Urogenital Diseases and Pregnancy Complications (1968) · Female Urogenital Diseases (1967) · Male Urogenital Diseases (1967) · Urogenital Diseases (1967) · Neoplasms, Glandular and Epithelial (1962) · Neoplasms by Histologic Type (1959) · Neoplasms by Site (1959) · Urologic Diseases (1959) · Adenocarcinoma (1953) · Kidney Diseases (1947) · Urogenital Neoplasms (1944) · Urologic Neoplasms (1944) · Carcinoma (1926) · Neoplasms (1810) · Kidney Neoplasms (1488)
Sunitinib (145) · Nivolumab (144) · pembrolizumab (139) · Sorafenib (84) · Bevacizumab (78) · Everolimus (74) · cabozantinib (71) · Axitinib (70) · pazopanib (65) · Ipilimumab (64) · aldesleukin (53) · Magnetic Resonance Spectroscopy (47) · Cyclophosphamide (42) · lenvatinib (42) · Interleukin-2 (39)
National Cancer Institute (NCI) (116) · Pfizer (72) · M.D. Anderson Cancer Center (54) · Novartis Pharmaceuticals (35) · Bristol-Myers Squibb (31) · Bayer (29) · Memorial Sloan Kettering Cancer Center (29) · Merck Sharp & Dohme LLC (25) · City of Hope Medical Center (23) · GlaxoSmithKline (21) · Case Comprehensive Cancer Center (19) · Hoffmann-La Roche (17) · Radboud University Medical Center (16) · RenJi Hospital (16) · Jonsson Comprehensive Cancer Center (15)
United States (1122) · China (214) · France (195) · United Kingdom (161) · Spain (158) · Canada (157) · Italy (149) · Germany (127) · Australia (124) · Netherlands (104) · South Korea (102) · Belgium (78) · Poland (71) · Japan (69) · Russia (66)
Eric Jonasch, MD (12) · Giuseppe Procopio, MD (9) · Sumanta K Pal (9) · Robert J. Motzer, MD (8) · Brian I. Rini, MD (5)
PMID 37146227, PMID 27238653, PMID 28410911, PMID 25577718, PMID 33526329, PMID 32499241, PMID 33058158, PMID 39462179, PMID 22980441, PMID 23964934, PMID 26702763, PMID 26706103, PMID 27279544, PMID 31401903, PMID 33947608, PMID 35304832, PMID 35383907, PMID 36848607, PMID 37526095, PMID 41969229, PMID 21917625, PMID 24338498, PMID 24687826, PMID 25532471, PMID 26406150, PMID 26457466, PMID 26685869, PMID 26969090, PMID 27101285, PMID 29377755, PMID 29439857, PMID 29563634, PMID 29788981, PMID 31371341, PMID 31992108, PMID 32171288, PMID 35031545, PMID 35166465, PMID 35420628, PMID 36064785, PMID 37093350, PMID 38396300, PMID 40712111, PMID 40791544, PMID 41484629, PMID 41861260, PMID 10751849, PMID 10984562, PMID 11282341, PMID 11410496
2023 (20), P30CA033572 (20), 2016 (18), 2018 (13), P30CA043703 (13), 2019 (10), 2017 (9), 2008 (8), 2015 (8), P30CA016672 (8), P30CA072720 (8), U10CA032102 (8), U10CA180820 (8), 2014 (7), P30CA014089 (7)